A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1-7 (txa-127) for the treatment of severe covid-19

HIGHLIGHTS

• who: Gebhard Wagener from the DepartmentColumbia University , West, th Street, PH, New York, NY, USA have published the paper: A randomized, placebo-controlled, double-blinded pilot study of angiotensin 1-7 (TXA-127) for the treatment of severe COVID-19, in the Journal: (JOURNAL) of February/09,/2021
• what: The aim of this study was to ascertain the safety of TXA-127 in COVID-19 and obtain data for the design of larger trials.

SUMMARY

Patients were recruited 3.8 ± 2.8 days after admission and 10.1 ± 3.5 days . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.